Open Demat
Be a Partner
Samadhan
Install App
Install App

11571

543635

PPLPHARMA

img img img img
Compare to down-arrow
View down-arrow
Display down-arrow
Studies down-arrow
No Data Available

PIRAMAL PHARMA LIMITED Share Price Update

As of the latest trading session, PIRAMAL PHARMA LIMITED is trading at ₹174.87, up by ₹0.30 or 0.17% from its previous close. The stock has moved between ₹171.52 and ₹179.36 today. Over the past year, the stock has delivered a return of -16.17%. In the last month, it has returned 17.75%.

PIRAMAL PHARMA LIMITED performance

Today’s low Today’s high
₹ 171.52 ₹ 179.36
₹ 174.87
52 week low 52 week high
₹ 132.30 ₹ 226.00
₹ 174.87
Open Price ₹ 174.71
Prev. Close ₹ 174.56
Volume (Shares) 3271327.00
Total traded value ₹ 5720.56
Upper Circuit ₹ 209.47
Lower Circuit ₹ 139.65
info

Investment Returns

Over 1 Month 17.75% Over 3 Months 6.59% Over 6 Months -10.53% Over 1 Year -16.17%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

PIRAMAL PHARMA LIMITED fundamentals


  • Market cap (Cr) 23,244.60
  • P/E Ratio (TTM) 33.20
  • Beta 1.18
  • Book Value / share 61.26
  • Return on equity 9.76%
  • EPS (TTM) 5.82
  • Dividend yield 0.00%
  • Net profit/quarter (Cr) 261.63
info icon alternate text
  • Market cap (Cr) 23,255.20
  • P/E Ratio (TTM) 33.20
  • Beta 1.05
  • Book Value / share 61.26
  • Return on equity 9.76%
  • EPS (TTM) 5.82
  • Dividend yield 0.00%
  • Net profit/quarter (Cr) 261.63
info icon alternate text

PIRAMAL PHARMA LIMITED Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition
info-icon
Revenue
Net income
Particulars MAR 2026 (Values in Cr)
Revenue 1489.06
Operating Expense 1275.33
Net Profit 261.63
Net Profit Margin (%) 17.57
Earnings Per Share (EPS) 1.97
EBITDA 421.47
Effective Tax Rate (%) 21.16
Particulars DEC 2025 (Values in Cr)
Revenue 1195.81
Operating Expense 1110.09
Net Profit 128.91
Net Profit Margin (%) 10.78
Earnings Per Share (EPS) 0.97
EBITDA 236.46
Effective Tax Rate (%) 16.79
Particulars SEP 2025 (Values in Cr)
Revenue 1127.26
Operating Expense 1081.82
Net Profit 196.33
Net Profit Margin (%) 17.41
Earnings Per Share (EPS) 1.48
EBITDA 329.04
Effective Tax Rate (%) 20.64
Particulars JUN 2025 (Values in Cr)
Revenue 969.88
Operating Expense 1008.22
Net Profit 113.14
Net Profit Margin (%) 11.66
Earnings Per Share (EPS) 0.85
EBITDA 225.25
Effective Tax Rate (%) 20.64
Particulars MAR 2025 (Values in Cr)
Revenue 1689.80
Operating Expense 1364.95
Net Profit 277.27
Net Profit Margin (%) 16.40
Earnings Per Share (EPS) 2.09
EBITDA 456.09
Effective Tax Rate (%) 23.90
Particulars MAR 2026 (Values in Cr)
Revenue 4782.01
Operating Expense 4475.46
Net Profit 700.01
Net Profit Margin (%) 14.63
Earnings Per Share (EPS) 5.28
EBITDA 1212.22
Effective Tax Rate (%) 20.16
Particulars MAR 2025 (Values in Cr)
Revenue 5285.71
Operating Expense 4581.92
Net Profit 691.40
Net Profit Margin (%) 13.08
Earnings Per Share (EPS) 5.22
EBITDA 1247.79
Effective Tax Rate (%) 24.11
Particulars MAR 2024 (Values in Cr)
Revenue 4390.11
Operating Expense 4084.54
Net Profit 391.22
Net Profit Margin (%) 8.91
Earnings Per Share (EPS) 3.05
EBITDA 819.98
Effective Tax Rate (%) 22.93
Particulars MAR 2023 (Values in Cr)
Revenue 3443.22
Operating Expense 3653.64
Net Profit 69.50
Net Profit Margin (%) 2.01
Earnings Per Share (EPS) 0.58
EBITDA 431.64
Effective Tax Rate (%) 43.81
Particulars MAR 2022 (Values in Cr)
Revenue 3340.42
Operating Expense 3087.80
Net Profit 367.54
Net Profit Margin (%) 11.00
Earnings Per Share (EPS) 3.12
EBITDA 684.99
Effective Tax Rate (%) 20.50
Particulars MAR 2025 (Values in Cr)
Book Value / Share 61.35
ROE % 1.14
ROCE % 6.43
Total Debt to Total Equity 0.60
EBITDA Margin 18.06
Particulars MAR 2024 (Values in Cr)
Book Value / Share 59.80
ROE % 0.22
ROCE % 5.40
Total Debt to Total Equity 0.70
EBITDA Margin 17.47
Particulars MAR 2023 (Values in Cr)
Book Value / Share 56.76
ROE % -2.77
ROCE % 1.90
Total Debt to Total Equity 0.72
EBITDA Margin 12.72
Particulars MAR 2022 (Values in Cr)
Book Value / Share 56.47
ROE % 6.11
ROCE % 6.91
Total Debt to Total Equity 0.58
EBITDA Margin 19.35
Particulars MAR 2021 (Values in Cr)
Book Value / Share 56.35
ROE % 14.90
ROCE % 12.67
Total Debt to Total Equity 0.54
EBITDA Margin 26.25
Particulars MAR 2025 (Values in Cr)
Book Value / Share 56.27
ROE % 9.76
ROCE % 12.31
Total Debt to Total Equity 0.17
EBITDA Margin 23.61
Particulars MAR 2024 (Values in Cr)
Book Value / Share 50.74
ROE % 6.53
ROCE % 8.27
Total Debt to Total Equity 0.24
EBITDA Margin 18.68
Particulars MAR 2023 (Values in Cr)
Book Value / Share 44.09
ROE % 1.34
ROCE % 3.62
Total Debt to Total Equity 0.27
EBITDA Margin 12.54
Particulars MAR 2022 (Values in Cr)
Book Value / Share 43.20
ROE % 7.97
ROCE % 9.82
Total Debt to Total Equity 0.15
EBITDA Margin 20.51
Particulars MAR 2021 (Values in Cr)
Book Value / Share 41.23
ROE % 13.94
ROCE % 16.15
Total Debt to Total Equity 0.04
EBITDA Margin 28.42
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 501.46
Total Assets 15677.59
Total Liabilities 15677.59
Total Equity 8125.47
Share Outstanding 132
Price to Book Ratio 3.99
Return on Assets (%) 0.58
Return on Capital (%) 0.71
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 482.56
Total Assets 15311.81
Total Liabilities 15311.81
Total Equity 7911.37
Share Outstanding 132
Price to Book Ratio 2.54
Return on Assets (%) 0.11
Return on Capital (%) 0.14
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 307.56
Total Assets 14522.56
Total Liabilities 14522.56
Total Equity 6773.50
Share Outstanding 119
Price to Book Ratio 1.55
Return on Assets (%) -1.28
Return on Capital (%) -1.52
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 328.99
Total Assets 12797.04
Total Liabilities 12797.04
Total Equity 6696.60
Share Outstanding 118
Price to Book Ratio 0.00
Return on Assets (%) 2.93
Return on Capital (%) 3.51
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 405.62
Total Assets 10899.78
Total Liabilities 10899.78
Total Equity 5605.00
Share Outstanding 99
Price to Book Ratio 0.00
Return on Assets (%) 7.66
Return on Capital (%) 9.81
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 177.84
Total Assets 10391.83
Total Liabilities 10391.83
Total Equity 7452.54
Share Outstanding 132
Price to Book Ratio 3.99
Return on Assets (%) 6.65
Return on Capital (%) 7.97
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 241.73
Total Assets 9550.88
Total Liabilities 9550.88
Total Equity 6712.07
Share Outstanding 132
Price to Book Ratio 2.54
Return on Assets (%) 4.09
Return on Capital (%) 4.97
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 64.16
Total Assets 8042.40
Total Liabilities 8042.40
Total Equity 5261.79
Share Outstanding 119
Price to Book Ratio 1.55
Return on Assets (%) 0.86
Return on Capital (%) 1.01
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 137.23
Total Assets 7371.04
Total Liabilities 7371.04
Total Equity 5123.12
Share Outstanding 118
Price to Book Ratio 0.00
Return on Assets (%) 4.98
Return on Capital (%) 5.86
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 152.35
Total Assets 5756.67
Total Liabilities 5756.67
Total Equity 4100.62
Share Outstanding 99
Price to Book Ratio 0.00
Return on Assets (%) 9.92
Return on Capital (%) 13.4
Particulars MAR 2025 (Values in Cr)
Net Income 341.71
Cash from Operations 1226.66
Cash from Investing -477.46
Cash from Financing -440.83
Net change in Cash -25.99
Free Cash Flow 1891.04
Particulars MAR 2024 (Values in Cr)
Net Income 119.80
Cash from Operations 1161.38
Cash from Investing -434.01
Cash from Financing -422.36
Net change in Cash 148.17
Free Cash Flow 1873.42
Particulars MAR 2023 (Values in Cr)
Net Income -160.56
Cash from Operations 672.89
Cash from Investing -1338.78
Cash from Financing 817.79
Net change in Cash -37.10
Free Cash Flow 1637.63
Particulars MAR 2022 (Values in Cr)
Net Income 441.03
Cash from Operations 935.84
Cash from Investing -1812.10
Cash from Financing 794.19
Net change in Cash -251.49
Free Cash Flow 1825.35
Particulars MAR 2021 (Values in Cr)
Net Income 639.68
Cash from Operations 742.09
Cash from Investing -4479.93
Cash from Financing 3976.83
Net change in Cash 94.48
Free Cash Flow 1344.28
Particulars MAR 2025 (Values in Cr)
Net Income 911.14
Cash from Operations 783.06
Cash from Investing -549.98
Cash from Financing -61.74
Net change in Cash -62.95
Free Cash Flow 1065.84
Particulars MAR 2024 (Values in Cr)
Net Income 507.62
Cash from Operations 436.10
Cash from Investing -635.52
Cash from Financing 451.38
Net change in Cash 174.15
Free Cash Flow 761.66
Particulars MAR 2023 (Values in Cr)
Net Income 123.69
Cash from Operations 131.55
Cash from Investing -435.05
Cash from Financing 290.12
Net change in Cash -73.41
Free Cash Flow 376.41
Particulars MAR 2022 (Values in Cr)
Net Income 477.41
Cash from Operations 351.85
Cash from Investing -1245.61
Cash from Financing 896.40
Net change in Cash -100.02
Free Cash Flow 584.67
Particulars MAR 2021 (Values in Cr)
Net Income 349.11
Cash from Operations 130.01
Cash from Investing -4382.89
Cash from Financing 4494.16
Net change in Cash 145.99
Free Cash Flow 188.12
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 32.34 14.00 1.67 247.83 23.12 40.44
BLISS GVS PHARMA LTD 278.20 22.51 2.46 2943.05 117.20 293.15
CIPLA LTD. 1431.55 28.35 3.35 115640.69 1165.55 1672.20
FERMENTA BIOTECH LIMITED 295.25 9.82 2.22 868.95 256.40 399.00
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 32.34 31.10 4.50 247.83 23.12 40.44
AMRUTAJAN HEALTH LTD 558.00 25.01 4.35 1613.21 490.00 789.95
ASTRAZENECA PHARMA IND LT 8488.45 102.01 26.55 21221.13 7630.00 10653.05
BLISS GVS PHARMA LTD 278.20 29.91 2.54 2943.05 117.20 293.15

PIRAMAL PHARMA LIMITED shareholding pattern

Holding
19.35%
34.85%
30.17%
15.61%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

News

Left Arrow
Right Arrow

PIRAMAL PHARMA LIMITED Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
174.87 0.17 redarrow
red-green-graph indicator
3 Bearish
13 Bullish
  • 5 Days 175.70
  • 26 Days 164.70
  • 10 Days 173.30
  • 50 Days 160.30
  • 12 Days 172.00
  • 100 Days 163.00
  • 20 Days 167.30
  • 200 Days 173.00
175.68 PIVOT
First Support 172.29 First Resistance 177.94 Second Support 170.03 Second Resistance 181.33 Third Support 166.64 Third Resistance 183.59
RSI 61.09 ADX 51.64 MACD 7.33 Williams % R -53.52 Commodity Channel Index (CCI) 64.86
Date 2026-05-15 Week 1962632.00 Same Day 818495.00 Month 2185304.00
1 Year 1.18 3 Year 0.93
Over 1 Month
17.75% down
Over 1 Year
-16.17% down
Over 3 Months
6.59% down
Over 3 Years
34.22% down
Over 6 Months
-10.53% down
Over 5 Years
0.00% down

PIRAMAL PHARMA LIMITED Corporate Actions

Dividend date Dividend amount Dividend type Record date Instrument type
16 Jul 2025 0.14 Final 16 Jul 2025 Equity shares
12 Jul 2024 0.11 Final 12 Jul 2024 Equity shares
Dividend date Dividend amount Dividend type Record date Instrument type
16 Jul 2025 0.14 Final 16 Jul 2025 Equity shares
12 Jul 2024 0.11 Final 12 Jul 2024 Equity shares

Top Gainers

up-arrow (%)

Top Losers

up-arrow (%)

Piramal Pharma Share Result Highlights

ParticularsSep 2024 (₹ Cr)Jun 2024 (₹ Cr)Mar 2024 (₹ Cr)Dec 2023 (₹ Cr)Sep 2023 (₹ Cr)
Revenue1284.391063.201525.301024.14994.24
Operating Expense1115.06988.301215.82967.58987.13
Net Profit210.0685.27273.0874.3477.16
Net Profit Margin (%)16.358.0217.907.257.76
Earnings Per Share (EPS)1.590.642.060.560.61
EBITDA359.27188.39442.83158.64175.24
Effective Tax Rate (%)23.8123.6324.7017.0819.78

Key Highlights

  • Revenue increased to ₹1284.39 Cr in Sep 2024, significantly higher than ₹1063.20 Cr in Jun 2024.
  • Net Profit saw a sharp rise to ₹210.06 Cr in Sep 2024, compared to ₹85.27 Cr in Jun 2024, showing substantial growth.
  • Net Profit Margin improved to 16.35% in Sep 2024, reflecting better profitability compared to 8.02% in Jun 2024.
  • Earnings Per Share (EPS) rose to ₹1.59 in Sep 2024, a strong improvement over ₹0.64 in Jun 2024.
  • EBITDA was ₹359.27 Cr in Sep 2024, indicating a strong operational performance.

Piramal Pharma Share Annual Reports

ParticularsValue (₹ Cr)
Revenue4390.11
Operating Expense4084.54
Net Profit391.22
Net Profit Margin (%)8.91
Earnings Per Share (EPS)3.05
EBITDA819.98
Effective Tax Rate (%)22.93

Key Highlights

  • Revenue of ₹4390.11 crore.
  • Operating expense of ₹4084.54 crore.
  • Net profit of ₹391.22 crore.
  • Net profit margin at 8.91%.
  • EPS of ₹3.05.
  • EBITDA of ₹819.98 crore.
  • Effective tax rate of 22.93%.
  • Piramal Pharma share price increased by 117.43% in the past year.

Piramal Pharma Share Dividend

ParticularsValue
Dividend Yield0.04%
Earnings Per Share (EPS)₹3.05
Net Profit₹391.22 Cr
Piramal Pharma Share Price₹273.45

Key Highlights

  • Dividend yield of 0.04%.
  • EPS of ₹3.05.
  • Net profit of ₹391.22 crore.
  • Piramal Pharma share price at ₹273.45.

Popular FAQs

1. Who is the CEO of Piramal Pharma Ltd?

The CEO of Piramal Pharma Ltd is Nandini Piramal. She is also the Chairperson of Piramal Enterprises Ltd, which is the parent company of Piramal Pharma Ltd. Under her leadership, the company has expanded its offerings in the pharmaceutical sector, including drug discovery, development, and manufacturing services.

 

2. When was Piramal Pharma Ltd established?

Piramal Pharma Ltd was incorporated on March 4, 2020, as a public limited company. The company was subsequently registered with the Registrar of Companies (RoC). It came into existence as a part of Piramal Enterprises Ltd's strategic reorganisation, which aimed to demerge its pharmaceutical business and expand its capabilities in drug manufacturing, biologics, vaccines, and self-care products.

 

3. What factors influence the Piramal Pharma Share Price?

The Piramal Pharma share price is influenced by various factors, including the company’s financial performance, industry growth, and global demand for pharmaceutical products. Key drivers include the company’s expansion into biologics and vaccines, joint ventures with companies like Allergan (now AbbVie), and the launch of new products. Other factors such as regulatory changes, competition in the pharmaceutical industry, and global market conditions also impact the Piramal Pharma share price.

 

4. Is Piramal Pharma Ltd debt-free?

No, Piramal Pharma Ltd is not debt-free. The company has undertaken strategic acquisitions and investments, which sometimes involve debt financing. However, Piramal Pharma has a strong portfolio of differentiated products and services, a global manufacturing footprint, and an expanding distribution network that support its ability to manage and service its debt.

 

5. What is the CAGR of Piramal Pharma Share?

The Compound Annual Growth Rate (CAGR) of the Piramal Pharma share price is not readily available for 10 years and 5 years. However, the share price has performed well over the past year, with a notable increase of 117%. This growth is indicative of the company’s positive trajectory, particularly following the demerger from Piramal Enterprises Ltd and its strategic investments and acquisitions.

 

6. How has the Piramal Pharma Share Price performed over the past year?

The Piramal Pharma share price has performed exceptionally well over the past year, with a significant increase of 117%. This growth can be attributed to the company's strategic initiatives, including the expansion of its product offerings, the successful demerger from Piramal Enterprises, and its continued expansion into high-demand sectors such as biologics and vaccines. The company has also strengthened its global presence, which has positively impacted investor confidence and share price performance.

PIRAMAL PHARMA LIMITED Share Price

Piramal Pharma Limited was incorporated on March 4, 2020 as a Public Limited Company and registered with the RoC. The Company offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 17 global facilities and a global distribution network in over 100 countries. It includes an integrated CDMO business, CHG business and ICH business, selling over-the-counter products in India. In addition, it has a joint venture with Allergan, a leader in ophthalmology in the Indian formulations market.

PPL is a leading pharmaceutical company with global operations, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and global distribution network. It operate under three business verticals - Piramal Pharma Solutions, an integrated contract development and manufacturing organization (CDMO) having a product suite in niche areas such as highly potent Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), antibody drug conjugates, potent sterile injectable, hormonal oral solid dosage forms, biologics and vaccines; Piramal Critical Care, a complex hospital generics (CHG) business in the areas of inhalation anaesthesia, injectable anaesthesia and pain management, intrathecal therapy and other injectable; and India consumer healthcare (ICH) business, selling well-known OTC brands.

Apart from this, the Company offers differentiated capabilities in niches areas such as highly potent APIs, antibody drug conjugates, potent sterile injectables, hormonal oral solid dosage forms and biologics and vaccines. The global distribution network gives it access to offer services and products to customers including large global pharma companies, biotech companies, hospitals and institutions.

In June 2020, the Company acquired pharmaceutical business from Piramal Enterprises Limited (PEL).

In October 2020, the Company received growth equity investment from the Carlyle Group. In It acquired 100% stake in Convergence Chemicals Private Limited (CCPL). It announced expansion for antibody drug conjugates at its Grangemouth (UK) facility and expansion of drug substance capabilities at its Riverview facility (USA).

In 2021, it acquired Hemmo Pharmaceuticals Private Limited (HPPL), into the development and manufacturing of peptide APIs.

On 7th October 2021, the Composite Scheme of Arrangement, which was entered into between the Company, Piramal Enterprises Limited, Convergence Chemicals Private Limited (CCPL), Hemmo Pharmaceuticals Private Limited (HPPL), PHL Fininvest Private Limited (PFPL) and their respective shareholders and creditors for demerger of Pharma Business from Piramal Enterprises Limited (PEL) to Company, amalgamation of CCPL and HPPL (both being wholly owned subsidiaries of the Company) into Company; and the amalgamation of PFPL (a wholly owned subsidiary of PEL) into PEL became effective from August 18, 2022.

In consideration for the demerger, the equity shareholders of PEL as on the demerger record date received 4 equity shares of face and paid-up value of Rs 10 each of the Company for every 1 equity share of face and paid-up value of Rs 2 each held in PEL. i.e. 4:1. Accordingly, the Company was listed on the Stock Exchanges, BSE Limited (BSE) and National Stock Exchange of India Limited 'NSE) on October 19, 2022.

In 2022, the Company acquired minority stake in Yapan Bio Private Limited, an India-Based CDMO providing expertise in biologics and vaccines. It launched 26 New products and 37 new SKUs during FY 2023.

In FY24, Company launched 27 new products and 24 new SKUs ; launched 21 new products and 31 new SKUs in FY 2025. The Company commenced manufacturing lines at Digwal to supplement Sevoflurane manufacturing capacity at Bethlehem (US) in FY 2025.

Parent organization Piramal Ajay G
NSE symbol PPLPHARMA
Founded 2020
stock
Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Nandini Piramal Chairperson & Whole Time Director
Peter D Deyoung WTD & Executive Director
Vivek Valsaraj Executive Director & CFO
Amit Jain Non-Exec & Non-Independent Dir
S Rama Dorai Independent Non Exe. Director
Jairaj Manohar Purandare Independent Non Exe. Director
Sridhar Gorthi Independent Non Exe. Director
Peter Stevenson Independent Non Exe. Director
Nathalie Leitch Non-Exec & Non-Independent Dir
Vibha Paul Rishi Independent Non Exe. Director
Maneesh Sharma Company Sec. & Compli. Officer
Right Arrow

Similar stocks

Left Arrow
similar-logo SUNPHARMA
0.80%
1878.2 15.00
down-arrow
similar-logo DIVISLAB
-2.32%
6760.5 -161.00
down-arrow
similar-logo TORNTPHARM
0.04%
4405.7 1.80
down-arrow
similar-logo CIPLA
-0.31%
1432.1 -4.59
down-arrow
similar-logo DRREDDY
2.53%
1336.7 33.09
down-arrow
similar-logo LUPIN
0.79%
2276.2 18.00
down-arrow
similar-logo MANKIND
1.65%
2503 40.80
down-arrow
similar-logo ZYDUSLIFE
2.01%
1011.7 20.00
down-arrow
similar-logo AUROPHARMA
0.05%
1511.8 0.90
down-arrow
similar-logo LAURUSLABS
0.61%
1323.6 8.09
down-arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of Piramal Pharma Ltd?

Answer Field

Piramal Pharma Ltd share price is for NSE ₹ 174.87 & for BSE ₹ 174.95 as on May 15 2026 03:30 PM.

What is the Market Cap of Piramal Pharma Ltd Share?

Answer Field

The market cap of Piramal Pharma Ltd for NSE ₹ 0.00 & for BSE ₹ 0.00 as on May 15 2026 03:30 PM.

What is the 52 Week High and Low of Piramal Pharma Ltd?

Answer Field

The 52 Week High and Low of Piramal Pharma Ltd for NSE is ₹ 226.00 and ₹ 132.30 and for BSE is ₹ 226.00 and ₹ 132.50.

What is 1 year return for Piramal Pharma Ltd?

Answer Field

The 1 year returns on the stock has been -16.17%.

What is the P/E Ratio of Piramal Pharma Ltd Share?

Answer Field

As on May 15 2026 03:30 PM the price-to-earnings (PE) ratio for Piramal Pharma Ltd share is 33.20.

What is the PB ratio of Piramal Pharma Ltd Share?

Answer Field

As on May 15 2026 03:30 PM, the price-to-book (PB) ratio for Piramal Pharma Ltd share is 61.26.

How to Buy Piramal Pharma Ltd Share?

Answer Field

You can trade in Piramal Pharma Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Piramal Pharma Ltd Share on Bajaj Broking App?

Answer Field

To buy Piramal Pharma Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Piramal Pharma Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

Who is the CEO of Piramal Pharma Ltd?

Answer Field

The CEO of Piramal Pharma Ltd is Nandini Piramal. She is also the Chairperson of Piramal Enterprises Ltd, which is the parent company of Piramal Pharma Ltd. Under her leadership, the company has expanded its offerings in the pharmaceutical sector, including drug discovery, development, and manufacturing services.

When was Piramal Pharma Ltd established?

Answer Field

Piramal Pharma Ltd was incorporated on March 4, 2020, as a public limited company. The company was subsequently registered with the Registrar of Companies (RoC). It came into existence as a part of Piramal Enterprises Ltd's strategic reorganisation, which aimed to demerge its pharmaceutical business and expand its capabilities in drug manufacturing, biologics, vaccines, and self-care products.

What factors influence the Piramal Pharma Share Price?

Answer Field

The Piramal Pharma share price is influenced by various factors, including the company’s financial performance, industry growth, and global demand for pharmaceutical products. Key drivers include the company’s expansion into biologics and vaccines, joint ventures with companies like Allergan (now AbbVie), and the launch of new products. Other factors such as regulatory changes, competition in the pharmaceutical industry, and global market conditions also impact the Piramal Pharma share price.

Is Piramal Pharma Ltd debt-free?

Answer Field

No, Piramal Pharma Ltd is not debt-free. The company has undertaken strategic acquisitions and investments, which sometimes involve debt financing. However, Piramal Pharma has a strong portfolio of differentiated products and services, a global manufacturing footprint, and an expanding distribution network that support its ability to manage and service its debt.

What is the CAGR of Piramal Pharma Share?

Answer Field

The Compound Annual Growth Rate (CAGR) of the Piramal Pharma share price is not readily available for 10 years and 5 years. However, the share price has performed well over the past year, with a notable increase of 117%. This growth is indicative of the company’s positive trajectory, particularly following the demerger from Piramal Enterprises Ltd and its strategic investments and acquisitions.

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Products

arrow

Calculators

arrow

Platforms

arrow

Mutual Funds & SIP

arrow

Important Links

arrow

Explore

arrow

Corporate

arrow

Discover

arrow

Popular Stocks

arrow

Indian Indices

arrow

Global Indices

arrow

Sector Wise Stocks

arrow

IPO

arrow

ATTENTION INVESTORS:

“Investments in securities market are subject to market risk, read all the scheme related documents carefully before investing."

"Prevent Unauthorized transactions in your Trading/Demat Account. Update your mobile numbers/email IDs with your stock brokers/Depository Participant. Receive alerts/information of your transaction/all debit and other important transactions in your Trading/ Demat Account directly from Exchange/CDSL/NSDL at the end of the day. Issued in the interest of investors."

" We collect, retain, and use your contact information for legitimate business purposes only, to contact you and to provide you information & latest updates regarding our products & services."  

"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."

"We understand that certain investment advisors may be approaching members of the public including our clients, representing that they are our partners, or representing that their investment advice is based on our research. Please note that we have not engaged any third parties to render any investment advisory services on our behalf nor are we providing any stock recommendations/tips/research report/advisory. Persons making investments on the basis of such advice may lose all or a part of their investments along with the fee paid to such unscrupulous persons. Please be cautious about any phone call that you may receive from persons representing to be such investment advisors, or a part of research firm offering advice on securities. Do not make payments through e-mail links, WhatsApp or SMS. Please do not share your personal or financial information with any person without proper verification. Always trade through a registered broker."

Bajaj Financial Securities Limited is a subsidiary of Bajaj Finance Limited and is a corporate trading and clearing member of BSE Ltd. and National Stock Exchange of India Ltd. (NSEIL), and also a Depository participant with National Securities Depository Ltd (“NSDL”) and Central Depository Services Ltd. (“CDSL”).

Bajaj Financial Securities Limited is engaged in the business of Stock Broking and as a Depository Participant.Bajaj Financial Securities Limited does not provide any advisory services to its clients. Bajaj Financial Securities Limited may share updates from time to time (through various electronic communication modes) which are sourced from public domain and the same are NOT to be construed as any advice or recommendation from Bajaj Financial Securities Limited. Client is requested to independently evaluate and/or consult their professional advisors before arriving at any conclusion to make any investment. The decision to invest shall be the sole responsibility of the Client and shall not hold Bajaj Financial Securities Limited, its employees and associates responsible for any losses, damages of any type whatsoever.

BSE Ltd. is not in any manner answerable, responsible or liable to any person or persons for any acts of omission or commission, errors, mistakes and/or violation, actual or perceived, by us or our partners, agents, associates etc., of any of the Rules, Regulations, Bye-laws of the Stock Exchange, Mumbai, SEBI Act or any other laws in force from time to time.

BSE Ltd. is not answerable, responsible or liable for any information on this Website or for any services rendered by our employees, our servants, and us.

Personal Loan, Fixed Deposit, EMI Card are provided by Bajaj Finance Limited. Bajaj Financial Securities Limited is only a distributor. These are not exchange traded products and all disputes with respect to the distribution activity, would not have access to exchange investor redressal forum or Arbitration mechanism.

No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.

Please Note:

  1. Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020

  2. Update your mobile number & email ID with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge.

  3. Pay 20% upfront margin of the transaction value to trade in cash market segment.

  4. Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 and BSE vide notice no. 20200731-7 dated July 31, 2020 and 20200831-45 dated August 31, 2020 and other guidelines issued from time to time in this regard.

  5. Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month.

Client Registration Documents (Rights & Obligations, Risk Disclosure Document, Do's & Don'ts) in Vernacular Language: BSE | NSE

If the client wishes to revoke /cancel the EDIS mandate placed by them, they can write on email us or call on the toll free number.

Advisory for Investors : NSE | BSE

We also do pro-account trading in Equity & Derivatives Segment.

Filling complaints on SCORES - Easy & Quick

A.  Register on SCORES portal B. Mandatory details for filling complaints on SCORES (i) Name, PAN, Address, Mobile Number, E-mail ID C. Benefits: (i) Effective Communication (ii) Speedy redressal of the grievances.

SEBI Registration No.: INZ000218931 | BSE Cash/CDS/F&O (Member ID: 6706) | NSE Cash/F&O/CDS (Member ID: 90177) | MCX Member ID: 57680 | DP registration No : IN-DP-418-2019 | CDSL DP No.: 12088600 | NSDL DP No. IN304300 | AMFI Registration No.: ARN – 163403 Research Analyst SEBI Registration No. INH000010043

Compliance officer:

Mr. Boudhayan Ghosh 
TEL: 020-48574486
Email for any investor grievances or write to us for DP related matters.

DISCLAIMER

STANDARD DISCLAIMER

Investments in the securities market are subject to market risk, read all related documents carefully before investing.

Reg Office: Bajaj Auto Limited Complex, Mumbai –Pune Road Akurdi Pune 411035. Corporate Office: Bajaj Financial Securities Limited, 1st Floor, Mantri IT Park, Tower B, Unit No 9 & 10, Viman Nagar, Pune, Maharashtra 411014. SEBI Registration No.: INZ000218931 | BSE Cash/F&O/CDS (Member ID:6706) | NSE Cash/F&O/CDS (Member ID: 90177) | MCX Member ID: 57680 | DP registration No: IN-DP-418-2019 | CDSL DP No.: 12088600 | NSDL DP No. IN304300 | AMFI Registration No.: ARN –163403. 

Website: Bajaj Broking

RESEARCH DISCLAIMER

Broking services offered by Bajaj Financial Securities Limited | Registered Office: Bajaj Auto Limited Complex , Mumbai –Pune Road Akurdi Pune 411035 | Corporate Office: Bajaj Financial Securities Limited, 1st Floor, Mantri IT Park, Tower B, Unit No 9 & 10, Viman Nagar, Pune, Maharashtra 411014 | CIN: U67120PN2010PLC136026 | Research Analyst SEB I Registration No: INH000010043.

Details of Compliance Officer: 

Mr. Boudhayan Ghosh (For Broking/DP/Research)
Email | Contact No.: 020-4857 4486 

Investment in the securities involves risks, investor should consult his own advisors/consultant to determine the merits and risks of investment.

DISCLOSURES

Disclosures under the provisions of SEBI (Research Analysts) Regulations 2014 (Regulations) 

Bajaj Financial Securities Limited ("Bajaj Broking" or "Research Entity") is regulated by the Securities and Exchange Board of India ("SEBI") and is licensed to carry on the business of broking, depository services and related activities. There were no instances of non-compliance by Bajaj Financial Securities Limited on any matter related to the capital markets, resulting in significant and material disciplinary action during the last three years. This research report has been prepared and distributed byBajaj Financial Securities Limited in the capacity of a Research Analyst as per Regulation 22(1) of SEBI (Research Analysts) Regulations 2014 having SEBI Registration No. INH000010043. 

DISCLAIMER

This e-mail/ short message service (SMS) may contain confidential, proprietary or legally privileged information. It should not be used by anyone who is not the original intended recipient. If you have erroneously received this message, please delete it immediately and notify the sender. The recipient acknowledges thatBajaj Financial Securities Limited or its holding and/or associated companies, as the case may be, are unable to exercise control or ensure or guarantee the integrity of/over the contents of the information contained in e-mail /SMS transmissions and further acknowledges that any views expressed in this message are those of the individual sender and no binding nature of the message shall be implied or assumed unless the sender does so expressly with due authority of Bajaj Financial Securities Limited. This message is not intended as an offer or publication or solicitation for distribution for subscription of or purchase or sale of any securities or financial instrument(s) to anyone in whose jurisdiction such subscription etc. requires prior local regulatory clearance or is contrary to the local laws of the land in any manner or as an official confirmation of any transaction. Before opening any attachments, please check them for viruses and defects. 

This service / information is strictly confidential and is being furnished to you solely for your information. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose unless otherwise expressly authorised. This service / information is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subjectBajaj Financial Securities Limited and affiliates/ group/holding companies to any registration or licensing requirements within such jurisdiction. The distribution of this document in certain jurisdictions may be restricted by law, and persons in whose possession this document comes, should inform themselves about and observe any such restrictions.  

The data would be provided to the clients on an "as is" and "where-is" basis, without any warranty. Bajaj Financial Securities Limited or its subsidiaries and associated companies shall not be liable for any delay or any other interruption which may occur in providing the data due to any reason including network (Internet) reasons or snags in the system, breakdown of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of the Bajaj Financial Securities Limited or its subsidiaries and associated companies to provide the data. In no event shall the Bajaj Financial Securities Limited or its holding and associated companies be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data provided by the Bajaj Financial Securities Limited or its holding and associated companies.

ADDITIONAL DISCLAIMER FOR U.S. PERSONS

Bajaj Financial Securities Limited is not a registered broker-dealer under the U.S. Securities Exchange Act of 1934, as amended (the"1934 act") and under applicable state laws in the United States. In addition, Bajaj Financial Securities Limited is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by Bajaj Financial Securities Limited, including the products and services described herein are not available to or intended for U.S. persons. This email message does not constitute an offer or invitation to purchase or subscribe for any securities or solicitation of any investments or investment services and/or shall not be considered as an advertisement tool. "U.S. Persons" are generally defined as a natural person, residing in the United States or any entity organized or incorporated under the laws of the United States. US Citizens living abroad may also be deemed "US Persons" under certain rules.  

ADDITIONAL DISCLAIMER FOR CANADIAN PERSONS

Bajaj Financial Securities Limited is not a registered adviser or dealer under applicable Canadian securities laws nor has it obtained an exemption from the adviser and/or dealer registration requirements under such law. Accordingly, any brokerage and investment services provided by Bajaj Financial Securities Limited, including the products and services described herein are not available to or intended for Canadian persons.  

This mailer and its respective contents do not constitute an offer or invitation to purchase or subscribe for any securities or solicitation of any investments or investment services.  

DISCLAIMER FOR REPORT

DISCLOSURES UNDER THE PROVISIONS OF SEBI (RESEARCH ANALYSTS) REGULATIONS 2014 (REGULATIONS)

Bajaj Financial Securities Limited ("Bajaj Broking" or "Research Entity") is regulated by the Securities and Exchange Board of India ("SEBI") and is licensed to carry on the business of broking, depository services and related activities.  

This Report has been prepared by Bajaj Financial Securities Limited in the capacity of a Research Analyst having SEBI Registration No. INH000010043 and distributed as per SEBI (Research Analysts) Regulations 2014. This report does not constitute an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. The information contained herein is from publicly available data or other sources believed to be reliable. This report is provided for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. The user assumes the entire risk of any use made of this information. Each recipient of this report should make such investigation as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult his own advisors to determine the merits and risks of such investment. The investment discussed or views expressed may not be suitable for all investors.  

This information is strictly confidential and is being furnished to you solely for your information. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject Bajaj Financial Securities Limited and associates / group companies to any registration or licensing requirements within such jurisdiction. The distribution of this report in certain jurisdictions may be restricted by law, and persons in whose possession this report comes, should observe, any such restrictions. The information given in this report is as of the date of this report and there can be no assurance that future results or events will be consistent with this information. This information is subject to change without any prior notice. Bajaj Financial Securities Limited reserves the right to make modifications and alterations to this statement as may be required from time to time. Bajaj Financial Securities Limited or any of its associates / group companies shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. Bajaj Financial Securities Limited is committed to providing independent and transparent recommendation to its clients. Neither Bajaj Financial Securities Limited nor any of its associates, group companies, directors, employees, agents or representatives shall be liable for any damages whether direct, indirect, special or consequential including loss of revenue or lost profits that may arise from or in connection with the use of the information. Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein. Past performance is not necessarily a guide to future performance .The disclosures of interest statements incorporated in this report are provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. The information provided in these reports remains, unless otherwise stated, the copyright of Bajaj Financial Securities Limited. All layout, design, original artwork, concepts and other Intellectual Properties, remains the property and copyright of Bajaj Financial Securities Limited and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the copyright holders.  

We offer our research services to clients as well as our prospects. Though this report is disseminated to all the customers simultaneously, not all customers may receive this report at the same time. We will not treat recipients as customers by virtue of their receiving this report.  

Bajaj Financial Securities Limited and its associates, officer, directors, and employees, research analyst (including relatives) worldwide may: (a) from time to time, have long or short positions in, and buy or sell the securities thereof, of company(ies), mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company/company(ies) discussed herein or act as advisor or lender/borrower to such company(ies) or have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance. Bajaj Financial Securities Limited may have proprietary long/short position in the above-mentioned scrip(s) and therefore should be considered as interested. The views provided herein are general in nature and do not consider risk appetite or investment objective of any particular investor; readers are requested to take independent professional advice before investing. This should not be construed as invitation or solicitation to do business with Bajaj Financial Securities Limited.  

Bajaj Financial Securities Limited or its associates may have received compensation from the subject company in the past 12 months. Bajaj Financial Securities Limited or its associates may have managed or co-managed public offering of securities for the subject company in the past 12 months. Bajaj Financial Securities Limited or its associates may have received compensation for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. Bajaj Financial Securities Limited or its associates may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. Bajaj Financial Securities Limited or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Research analyst or his/her relative or Bajaj Financial Securities Limited’s associates may have financial interest in the subject company. Bajaj Financial Securities Limited, its associates, research analyst and his/her relative may have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance.  

Research analyst has served as an officer, director or employee of subject Company: No  

Bajaj Financial Securities Limited has financial interest in the subject companies: No  

Bajaj Financial Securities Limited’s Associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report.  

Research analyst or his/her relative has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No  

Bajaj Financial Securities Limited has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No  

Subject company may have been client during twelve months preceding the date of distribution of the research report.  

There were no instances of non-compliance by Bajaj Financial Securities Limited on any matter related to the capital markets, resulting in significant and material disciplinary action during the last three years. A graph of daily closing prices of the securities is also available at NSE

ANALYST CERTIFICATION

The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.  

RISK DISCLOSURE ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

BROKERAGE DISCLAIMER

All leveraged intraday positions will be squared off on the same day. There is no restriction on the withdrawal of the unutilised margin amount. Brokerage will not exceed the SEBI prescribed limit. Visit : Pricing

MTF 

As subject to the provisions of SEBI Circular CIR/MRD/DP/54/2017 dated June 13, 2017, and the terms and conditions mentioned in the lights and obligations statement issued by the TM (if applicable).  

US INVESTING

International investment is not supervised by any regulatory body in India. Thus, any claim or dispute relating to such investment or enforcement of any agreement/contract /claim will not be under laws and regulations of the recognized stock exchanges and investor protection under Indian Securities Law. The account opening process will be carried out on Vested platform and Bajaj Financial Securities Limited will not have any role in it.  

IPO 

This should not be construed as soliciting investment. Investors’ discretion is required. Kindly consult your financial expert before investing. No need to issue cheques by investors while subscribing to IPO. Investments in securities markets are subject to market risks, read all the related documents carefully before investing.  

SCREENERS 

Screeners is not Exchange-approved products and any disputes related to the same will not be dealt on the Exchange platform. 

SECURITIES 

Securities quoted are exemplary and not recommendatory. 

IPV 

Account would be open after all procedure relating to IPV and client due diligence is completed. 

IMAGES 

The images used are only for representation purpose. Proper due diligence has been done for the images and the image is not of any artist. The same is captured from royalty free sites.

THIRD PARTY PRODUCT DISCLAIMER

Bajaj Financial Securities Limited is a distributor for Non-Broking Products/Services such as Mutual Funds, Mutual Funds SIP, IPO, Bonds, Insurance, PMS, Global Investing, any other third-party products/services. These are not Exchange Traded Products, and we are only acting as distributors. All disputes with respect to the distribution activity, would not have access to SCORES/ODR, Exchange investor redressal forum or Arbitration mechanism. Please refer to the detailed disclaimer for Third-Party Products.

DISCLOSURE TO CLIENTS REGARDING PAYOUT OF FUNDS

As per SEBI circular no. SEBI/HO/MIRSD/MIRSD-PoD-1/P/CIR/2023/84 dated June 08, 2023, Stockbrokers are required to upstream the entire client funds lying with them to the Clearing Corporation. Based on client’s request the funds’ release request must be placed with the Clearing Corporation. Based on the internal process and cut-off timelines of the Clearing Corporation the funds will be released to the Stock Broker. In view of this new process, as specified by the regulatory and the cut-off time of Clearing Corporation/Banks processing the funds, Bajaj Financial Securities Limited cannot commit the exact time for releasing funds payout to its client. Clients are requested to note that, Bajaj Financial Securities Limited will not be responsible for any inconvenience caused to clients due to delay in release of funds payout, including fines, delayed charges, defaults, etc.